Jack A Schalken

The PCa models will be put offline on January 8th, 2019.
Interested in uro-oncology? Check out our new accredited PinPoint case platform on ppcp.mirrorsmed.org

Jack A Schalken

Radboud University Nijmegen Medical Centre, Urology

Dr. Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996, Dr. Schalken was appointed as professor of experimental oncology at the University of Utrecht. Since 2001, he is professor of experimental urology at the Radboud University (Nijmegen).

His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes:

  1. Unravelling the mechanism of GU cancer invasion/cadherin switching/EMT
  2. Cancer stem/initiating cells
  3. Targeted therapy in (GU) cancer
  4. Molecular diagnostics of prostate cancer (eg PCA3)
  5. Combining 1 thru 4 to make steps towards personalized medicine

Dr. Schalken is member of 12 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as ESUR, SBUR, EAU, ASCO and ESMO.

Dr. Schalken is (co)author on more than 325 peer reviewed publications, 74 book chapters and has edited 10 books/special journal issues. He supervised 33 completed PhD theses. He is inventor on approximately 20 patent applications (some still pending approval).